At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 60 enrolled
Drug / intervention
Parsaclisibdrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 2, Multicenter, International, Open-Label, Safety and Efficacy Study of INCB050465 in Subjects With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (CITADEL-202)
In Brief
A Phase 2 clinical trial evaluating Parsaclisib for Lymphoma. Completed, enrolled 60 participants across 70 sites in 11 countries.
Detailed Summary
The purpose of this study is to assess the safety and efficacy of parsaclisib in subjects with relapsed or refractory diffuse large B-cell lymphoma.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsLymphoma
CountriesAustralia, Belgium, Canada, Czechia, France, Italy, Poland, South Korea, Spain, United Kingdom, United States
Collaborators--
Timeline
Phase 2CompletedFinished
2017201820192020202120222023202420252026
First PostedDec 2016
Enrollment StartMar 2017
Primary CompletionFeb 2019
Study CompletionFeb 2021
TodayJul 2026
First PostedDec 20, 2016
Enrollment StartMar 2, 2017
Primary CompletionFeb 22, 2019
Study CompletionFeb 5, 2021
TodayJul 2, 2026
Enrollment to primary: 2.0 yearsPosted 9.5 years ago
Interventions
Parsaclisibdrug
Parsaclisib once daily for 8 weeks followed by once weekly